Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

NCT03506997 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Castration-resistant Prostate Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]